-

04:40:33 PM

LIVE Real Time SNGX Stock Market News

SNGX - Soligenix Inc

04/13/21 7:00 AM

Nasdaq : SNGX

Soligenix Announces Presentations at Prominent Scientific Conferences

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today planned conference

RHEA-AI

neutral

04/07/21 7:00 AM

Nasdaq : SNGX

Soligenix Receives Conditional FDA Acceptance of Proposed Brand Name HyBryte(TM) for SGX301 in CTCL

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the U.S. Food and

RHEA-AI

very positive

03/30/21 7:00 AM

Nasdaq : SNGX

Soligenix Announces Recent Accomplishments And Year-End 2020 Financial Results

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent

RHEA-AI

very positive

03/09/21 7:00 AM

Nasdaq : SNGX

Soligenix to Receive $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received

RHEA-AI

positive

03/04/21 7:00 AM

Nasdaq : SNGX

Soligenix Announces Positive Progress in the Pre-clinical Development of its COVID-19 Vaccine

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of

RHEA-AI

positive

02/24/21 7:00 AM

Nasdaq : SNGX

Soligenix Provides Important Highlights and Upcoming Catalysts in Corporate Update Letter

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its

RHEA-AI

positive

02/11/21 7:00 AM

Nasdaq : SNGX

Soligenix to Present at the 2021 BIO CEO & Investor Digital Conference

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and

RHEA-AI

neutral

02/01/21 7:00 AM

Nasdaq : SNGX

Soligenix Receives Hong Kong Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Hong Kong

RHEA-AI

very positive

01/19/21 7:00 AM

Nasdaq : SNGX

Soligenix Announces Investor Webcast Event: U.S. Commercialization of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be hosting an

RHEA-AI

neutral

01/07/21 7:00 AM

Nasdaq : SNGX

Soligenix Announces Strategic Partnership with Daavlin for Supply and Distribution of the SGX301 Companion Light Device in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has signed an

RHEA-AI

very positive